Adamis Pharmaceuticals (NASDAQ:ADMP) Announces Earnings Results

Adamis Pharmaceuticals (NASDAQ:ADMPGet Rating) released its quarterly earnings data on Monday. The specialty pharmaceutical company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.04), Fidelity Earnings reports. Adamis Pharmaceuticals had a negative net margin of 458.77% and a negative return on equity of 85.31%.

Shares of Adamis Pharmaceuticals stock opened at $0.46 on Tuesday. Adamis Pharmaceuticals has a 52-week low of $0.31 and a 52-week high of $1.48. The stock’s 50-day simple moving average is $0.51 and its 200 day simple moving average is $0.64.

A number of large investors have recently modified their holdings of the business. JPMorgan Chase & Co. increased its stake in shares of Adamis Pharmaceuticals by 735.2% in the fourth quarter. JPMorgan Chase & Co. now owns 218,573 shares of the specialty pharmaceutical company’s stock worth $132,000 after purchasing an additional 192,403 shares in the last quarter. Virtu Financial LLC lifted its stake in shares of Adamis Pharmaceuticals by 9.6% during the 4th quarter. Virtu Financial LLC now owns 224,561 shares of the specialty pharmaceutical company’s stock valued at $136,000 after buying an additional 19,691 shares in the last quarter. State Street Corp boosted its holdings in Adamis Pharmaceuticals by 13.1% in the 1st quarter. State Street Corp now owns 475,373 shares of the specialty pharmaceutical company’s stock worth $271,000 after buying an additional 55,168 shares during the period. Finally, Millennium Management LLC grew its stake in Adamis Pharmaceuticals by 3,449.4% in the 3rd quarter. Millennium Management LLC now owns 557,157 shares of the specialty pharmaceutical company’s stock valued at $540,000 after buying an additional 541,460 shares in the last quarter. Hedge funds and other institutional investors own 9.52% of the company’s stock.

Several analysts have recently commented on the company. StockNews.com started coverage on Adamis Pharmaceuticals in a research note on Saturday. They issued a “sell” rating for the company. Zacks Investment Research cut shares of Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, January 19th.

Adamis Pharmaceuticals Company Profile (Get Rating)

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose.

Further Reading

Earnings History for Adamis Pharmaceuticals (NASDAQ:ADMP)

Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.